Cargando…
Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study
BACKGROUND: Immune responses to vaccination vary widely between individuals. The aim of this study was to identify health-related variables potentially underlying the antibody responses to SARS-CoV-2 vaccination in older persons. We recruited participants in the long-running Doetinchem Cohort Study...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599057/ https://www.ncbi.nlm.nih.gov/pubmed/37880758 http://dx.doi.org/10.1186/s12979-023-00382-4 |
_version_ | 1785125694626332672 |
---|---|
author | Kuijpers, Yunus Picavet, H. Susan J. de Rond, Lia de Zeeuw-Brouwer, Mary-lène Rutkens, Ryanne Gijsbers, Esther Slits, Irene Engelfriet, Peter Buisman, Anne-Marie Verschuren, W. M. Monique |
author_facet | Kuijpers, Yunus Picavet, H. Susan J. de Rond, Lia de Zeeuw-Brouwer, Mary-lène Rutkens, Ryanne Gijsbers, Esther Slits, Irene Engelfriet, Peter Buisman, Anne-Marie Verschuren, W. M. Monique |
author_sort | Kuijpers, Yunus |
collection | PubMed |
description | BACKGROUND: Immune responses to vaccination vary widely between individuals. The aim of this study was to identify health-related variables potentially underlying the antibody responses to SARS-CoV-2 vaccination in older persons. We recruited participants in the long-running Doetinchem Cohort Study (DCS) who underwent vaccination as part of the national COVID-19 program, and measured antibody concentrations to SARS-CoV-2 Spike protein (S1) and Nucleoprotein (N) at baseline (T0), and a month after both the first vaccination (T1), and the second vaccination (T2). Associations between the antibody concentrations and demographic variables, including age, sex, socio-economic status (SES), comorbidities (cardiovascular diseases and immune mediated diseases), various health parameters (cardiometabolic markers, inflammation markers, kidney- and lung function) and a composite measure of frailty (‘frailty index’, ranging from 0 to 1) were tested using multivariate models. RESULTS: We included 1457 persons aged 50 to 92 years old. Of these persons 1257 were infection naïve after their primary vaccination series. The majority (N = 954) of these individuals were vaccinated with two doses of BNT162b2 (Pfizer) and their data were used for further analysis. A higher frailty index was associated with lower anti-S1 antibody responses at T1 and T2 for both men (R(T1) = -0.095, P(T1) = 0.05; R(T2) = -0.11, P(T2) = 0.02) and women (R(T1) = -0.24, P(T1) < 0.01; R(T2) = -0.15, P(T2) < 0.01). After correcting for age and sex the frailty index was also associated with the relative increase in anti-S1 IgG concentrations between the two vaccinations (β = 1.6, P < 0.01). Within the construct of frailty, history of a cardiac catheterization, diabetes, gastrointestinal disease, a cognitive speed in the lowest decile of the population distribution, and impaired lung function were associated with lower antibody responses after both vaccinations. CONCLUSIONS: Components of frailty play a key role in the primary vaccination response to the BNT162b2 vaccine within an ageing population. Older persons with various comorbidities have a lowered immune response after their first vaccination, and while frail and sick older persons see a stronger increase after their second vaccination compared to healthy people, they still have a lower antibody response after their second vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12979-023-00382-4. |
format | Online Article Text |
id | pubmed-10599057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105990572023-10-26 Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study Kuijpers, Yunus Picavet, H. Susan J. de Rond, Lia de Zeeuw-Brouwer, Mary-lène Rutkens, Ryanne Gijsbers, Esther Slits, Irene Engelfriet, Peter Buisman, Anne-Marie Verschuren, W. M. Monique Immun Ageing Research BACKGROUND: Immune responses to vaccination vary widely between individuals. The aim of this study was to identify health-related variables potentially underlying the antibody responses to SARS-CoV-2 vaccination in older persons. We recruited participants in the long-running Doetinchem Cohort Study (DCS) who underwent vaccination as part of the national COVID-19 program, and measured antibody concentrations to SARS-CoV-2 Spike protein (S1) and Nucleoprotein (N) at baseline (T0), and a month after both the first vaccination (T1), and the second vaccination (T2). Associations between the antibody concentrations and demographic variables, including age, sex, socio-economic status (SES), comorbidities (cardiovascular diseases and immune mediated diseases), various health parameters (cardiometabolic markers, inflammation markers, kidney- and lung function) and a composite measure of frailty (‘frailty index’, ranging from 0 to 1) were tested using multivariate models. RESULTS: We included 1457 persons aged 50 to 92 years old. Of these persons 1257 were infection naïve after their primary vaccination series. The majority (N = 954) of these individuals were vaccinated with two doses of BNT162b2 (Pfizer) and their data were used for further analysis. A higher frailty index was associated with lower anti-S1 antibody responses at T1 and T2 for both men (R(T1) = -0.095, P(T1) = 0.05; R(T2) = -0.11, P(T2) = 0.02) and women (R(T1) = -0.24, P(T1) < 0.01; R(T2) = -0.15, P(T2) < 0.01). After correcting for age and sex the frailty index was also associated with the relative increase in anti-S1 IgG concentrations between the two vaccinations (β = 1.6, P < 0.01). Within the construct of frailty, history of a cardiac catheterization, diabetes, gastrointestinal disease, a cognitive speed in the lowest decile of the population distribution, and impaired lung function were associated with lower antibody responses after both vaccinations. CONCLUSIONS: Components of frailty play a key role in the primary vaccination response to the BNT162b2 vaccine within an ageing population. Older persons with various comorbidities have a lowered immune response after their first vaccination, and while frail and sick older persons see a stronger increase after their second vaccination compared to healthy people, they still have a lower antibody response after their second vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12979-023-00382-4. BioMed Central 2023-10-25 /pmc/articles/PMC10599057/ /pubmed/37880758 http://dx.doi.org/10.1186/s12979-023-00382-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kuijpers, Yunus Picavet, H. Susan J. de Rond, Lia de Zeeuw-Brouwer, Mary-lène Rutkens, Ryanne Gijsbers, Esther Slits, Irene Engelfriet, Peter Buisman, Anne-Marie Verschuren, W. M. Monique Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study |
title | Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study |
title_full | Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study |
title_fullStr | Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study |
title_full_unstemmed | Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study |
title_short | Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study |
title_sort | potential determinants of antibody responses after vaccination against sars-cov-2 in older persons: the doetinchem cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599057/ https://www.ncbi.nlm.nih.gov/pubmed/37880758 http://dx.doi.org/10.1186/s12979-023-00382-4 |
work_keys_str_mv | AT kuijpersyunus potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT picavethsusanj potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT derondlia potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT dezeeuwbrouwermarylene potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT rutkensryanne potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT gijsbersesther potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT slitsirene potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT engelfrietpeter potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT buismanannemarie potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy AT verschurenwmmonique potentialdeterminantsofantibodyresponsesaftervaccinationagainstsarscov2inolderpersonsthedoetinchemcohortstudy |